These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 25961532)
21. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465 [TBL] [Abstract][Full Text] [Related]
22. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy? Izquierdo ME; Bonastre MT Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668 [TBL] [Abstract][Full Text] [Related]
23. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations. Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580 [TBL] [Abstract][Full Text] [Related]
24. Translational insights into gastrointestinal stromal tumor and current clinical advances. Hemming ML; Heinrich MC; Bauer S; George S Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284 [TBL] [Abstract][Full Text] [Related]
25. The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Boikos SA; Stratakis CA Endocrine; 2014 Nov; 47(2):401-8. PubMed ID: 25027296 [TBL] [Abstract][Full Text] [Related]
26. [Gastrointestinal stromal tumors: a rare nosological entity and a model example for the use of personalized therapy with a molecular basis]. Bettegazzi C; Erra S Recenti Prog Med; 2015 Jan; 106(1):52-7. PubMed ID: 25621782 [TBL] [Abstract][Full Text] [Related]
27. Epithelioid variant of gastrointestinal stromal tumor harboring PDGFRA mutation and MLH1 gene alteration: A case report. Kobayashi M; Inaguma S; Raffeld M; Kato H; Suzuki S; Wakasugi T; Mitsui A; Kuwabara Y; Lasota J; Ikeda H; Miettinen M; Takahashi S Pathol Int; 2019 Sep; 69(9):541-546. PubMed ID: 31273885 [TBL] [Abstract][Full Text] [Related]
28. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor. Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Oncology; 2016; 90(2):112-7. PubMed ID: 26779618 [TBL] [Abstract][Full Text] [Related]
29. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509 [TBL] [Abstract][Full Text] [Related]
30. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822 [TBL] [Abstract][Full Text] [Related]